From: Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis
Unmatched cohort | Propensity score matched cohort | |||||||
---|---|---|---|---|---|---|---|---|
Clinical variables | Sapien 3 (N = 689) | Perimount Magna Ease (N = 1311) | Standardized difference | p-value | Sapien 3 (N = 308) | Perimount Magna Ease (N = 308) | Standardized difference | p-value |
Age, yrs | 81.3 ± 6.4 | 74.0 ± 6.9 | 1.1 | < 0.0001 | 78.8 ± 6.9 | 79.0 ± 5.3 | −0.03 | 0.697 |
Female | 365 (53.0) | 556 (42.4) | 0.21 | < 0.0001 | 160 (51.9) | 165 (53.6) | −0.03 | 0.674 |
BMI, kg/m2 | 27.4 ± 4.9 | 28.0 ± 4.8 | −0.12 | 0.012 | 28.1 ± 5.2 | 28.0 ± 5.0 | 0.02 | 0.848 |
Diabetes mellitus | 207 (30.0) | 353 (26.9) | 0.07 | 0.140 | 93 (30.2) | 87 (28.2) | 0.04 | 0.578 |
Atrial fibrillation | 293 (42.5) | 255 (19.5) | 0.52 | < 0.0001 | 102 (33.1) | 99 (32.1) | 0.02 | 0.782 |
Extracardiac arteriopathy | 117 (17.0) | 137 (10.5) | 0.19 | < 0.0001 | 49 (15.9) | 41 (13.3) | 0.07 | 0.383 |
Chronic lung disease | 149 (21.6) | 172 (13.1) | 0.23 | < 0.0001 | 65 (21.1) | 62 (20.1) | 0.02 | 0.761 |
Hemoglobin, g/l | 125.7 ± 15.2 | 133.6 ± 15.1 | −0.53 | < 0.0001 | 128.7 ± 15.2 | 127.8 ± 15.3 | 0.06 | 0.421 |
eGFR, ml/m2/min | 62.0 ± 18.5 | 72.6 ± 16.7 | −0.60 | < 0.0001 | 65.6 ± 18.1 | 66.4 ± 16.1 | −0.05 | 0.550 |
History of stroke | 70 (10.2) | 70 (5.3) | 0.18 | 0.0001 | 27 (8.8) | 29 (9.4) | −0.02 | 0.782 |
Prior pacemaker | 65 (9.4) | 50 (3.8) | 0.23 | < 0.0001 | 20 (6.5) | 19 (6.2) | 0.01 | 0.862 |
Previous cardiac surgery | 110 (16.0) | 24 (1.8) | 0.51 | < 0.0001 | 17 (5.5) | 18 (5.8) | −0.01 | 0.847 |
Prior PCI | 140 (20.3) | 130 (9.9) | 0.29 | < 0.0001 | 47 (15.3) | 40 (13.0) | 0.07 | 0.370 |
Coronary artery disease | 181 (26.3) | 563 (42.9) | −0.36 | < 0.0001 | 102 (33.1) | 97 (31.5) | 0.04 | 0.665 |
No. of diseased vessels | 0.36 ± 0.7 | 0.78 ± 1.1 | −0.48 | < 0.0001 | 0.47 ± 0.8 | 0.46 ± 0.8 | 0.02 | 0.836 |
Recent MI | 17 (2.5) | 72 (5.5) | −0.16 | 0.0018 | 9 (2.9) | 9 (2.9) | 0.00 | 1.000 |
NYHA class IV | 82 (11.9) | 94 (7.2) | 0.16 | 0.0004 | 31 (10.1) | 34 (11.0) | −0.03 | 0.696 |
AHF | 75 (10.9) | 101 (7.7) | 0.11 | 0.017 | 33 (10.7) | 33 (10.7) | 0.00 | 1.000 |
Urgent procedure | 55 (8.0) | 148 (11.3) | −0.11 | 0.020 | 28 (9.1) | 33 (10.7) | −0.05 | 0.508 |
Ejection fraction | 0.26 | < 0.0001 | 0.08 | 0.699 | ||||
> 50% | 499 (72.4) | 1069 (81.5) | 230 (74.7) | 239 (77.6) | ||||
31–50% | 158 (22.9) | 220 (16.8) | 68 (22.1) | 60 (19.5) | ||||
21–30% | 31 (4.5) | 22 (1.7) | 10 (3.2) | 9 (2.9) | ||||
Sys. pulmonary pressure | 0.74 | < 0.0001 | 0.09 | < 0.0001 | ||||
31–55 mmHg | 245 (35.6) | 524 (40.0) | 131 (42.5) | 121 (39.3) | ||||
> 55 mmHg | 75 (10.9) | 92 (7.0) | 34 (11.0) | 39 (12.7) | ||||
Mitral valve regurgitation | 0.56 | < 0.0001 | 0.06 | 0.652 | ||||
Mild | 255 (37.0) | 278 (21.2) | 116 (37.7) | 107 (34.7) | ||||
Moderate | 80 (11.6) | 39 (3.0) | 23 (7.5) | 21 (6.8) | ||||
Concomitant coronary revascularization | 29 (4.2) | 511 (39.0) | −0.78 | < 0.0001 | 14 (4.5) | 84 (27.3) | −0.62 | < 0.0001 |
EuroSCORE II, % | 6.5 ± 7.1 | 3.4 ± 4.2 | 0.52 | < 0.0001 | 5.0 ± 5.2 | 4.9 ± 5.9 | 0.02 | 0.752 |
STS-PROM, % | 4.3 ± 2.9 | 2.6 ± 2.1 | 0.67 | < 0.0001 | 3.5 ± 2.2 | 3.5 ± 2.8 | 0.01 | 0.918 |